August 2012
-
Perrigo has announced that it has begun shipping its generic version of Astepro azelastine nasal spray after the ANDA it submitted in partnership with Impax Laboratories received final approval from the FDA. In January 2012,… Read more . . .
-
GlaxoSmithKline and Theravance have announced that they have received marketing authorization for the Anoro Ellipta umeclidinium/vilanterol DPI for the treatment of COPD in Europe. The EMA’s Committee for Medicinal Products for Human Use (CHMP) issues… Read more . . .
-
The Medicon Valley Inhalation Consortium (MVIC) has announced the addition of four new member companies, bringing the total to 24. The newly added companies are OM Projekt, Lastow Consulting, Competitive Intelligence Solutions (CIS), and AB… Read more . . .
-
Aptar Pharma has published a white paper summarizing a roundtable discussion on inhaler adherence held in Paris, France on November 29th 2013. The panel included five experts on inhaler usage from the UK and France.… Read more . . .
-
Device manufacturer Phillips-Medisize has announced that it will be acquired by Golden Gate Capital for an undisclosed amount. According to the announcement, Matt Jennings will remain as President and CEO, and the company will keep… Read more . . .
-
Discovery Laboratories has announced that the US Patent and Trademark Office (USPTO) has issued the company a new patent titled “Ventilation Circuit Adaptor and Proximal Aerosol Delivery System” (Patent No. 8,701,658) and Notices of Allowance… Read more . . .
-
According to 3M Drug Delivery Systems, the company will increase the capacity of its Loughborough, UK MDI facility by more than 20%. No additional details were provided. 3M DDS VP of Inhalation Drug Delivery Marcello… Read more . . .
-
Merck has announced the sale of its Consumer Care division, which markets Afrin oxymetazoline nasal spray, to Bayer. According to Bayer, “The purchase price of USD 14.2 billion includes a payment associated with sales of… Read more . . .
-
Propeller Health (formerly known as Asthmapolis) has announced that the latest version of its inhaler tracking system has received 510(k) clearance from the FDA. The system includes a sensor that snaps onto an MDI and… Read more . . .
-
Pulmatrix has announced that a recently completed Phase 1b study of its PUR0200 inhaled LAMA in COPD patients found that all three doses of PUR0200 produced significant improvement in lung function compared to placebo and… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland